glp-1 small molecule agonist A novel approach to exploit Small-Molecule glucagon-like Peptide-1 receptor agonists with high potency Orforglipron, an Oral Small-Molecule GLP-1

*Correspondence: Elisabet Jerlhag, [email protected] This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

Drug regimen simplicity is an important clinical consideration, particularly in patients receiving multiple medications for the treatment of T2DM and related comorbidities

Use of antihyperglycemic drugs and risk of cancer in patients with diabetes

GLP-1R agonists effect(s) on vascular smooth muscle cells are equally important to those on endothelial cells with several favorable responses being reported, including enhanced differentiation, attenuated response to reactive oxygen species, reduced vascular remodeling through improved mitochondrial activity and dynamics, and the prevention of aberrant migration [65]

Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: A systematic review and meta-analysis

Zhao H-J, Jiang X, Hu L-J, Yang L, Deng L-D, Wang Y-P, et al